Research programme - cancer therapeutics - Artios PharmaAlternative Names: DDR - cancer therapeutics - Artios Pharma; Pol-theta
Latest Information Update: 28 Sep 2016
At a glance
- Originator Cancer Research Technology
- Developer Artios Pharma
- Mechanism of Action DNA repair enzyme modulators; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer